Download PDF
Aktuelle Neurologie 2007; 34(2): 80-84
DOI: 10.1055/s-2006-951978
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Die Rolle von Plazebos in der Kopfschmerzforschung

The Role of Placebos in Headache ResearchH.-C.  Diener1 , C.  F.  Schorn1
  • 1Universitätsklinik für Neurologie, Universitätsklinikum Essen
Further Information

Publication History

Publication Date:
09 March 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Wirkung von Medikamenten oder nicht medikamentöser Therapie zur Behandlung von Kopfschmerzen kann nur durch die Durchführung von plazebokontrollierten Studien wissenschaftlich belegt werden. Um diese Studien wissenschaftlich sauber durchführen zu können, müssen die Einflussfaktoren bekannt sein, welche den Plazeboeffekt beeinflussen. Dazu gehören beispielsweise die Erwartungshaltung der Patienten, die Applikationsform des Plazebos (als Tablette oder Injektion) und die unterschiedliche Häufigkeit der Plazeboeinnahme als Akuttherapie sowie die prophylaktische Therapie der Kopfschmerzen. Nur wenn diese Einflussvariablen bekannt sind können optimale Studiendesigns entworfen und umgesetzt werden.

Abstract

The only way to appreciate the efficacy of drug and behavioural therapy in the treatment of headache is to perform placebo-controlled, randomised trials. In order to plan and conduct these studies in the most appropriate way any factors influencing the placebo response have to be known. This paper reviews these factors, for example, expectations and applications of placebo. Response rates to placebo in the treatment of acute headache episodes and headache prophylaxis and factors influencing those are reported. These variables have to be known to properly calculate the power of planned randomised trials.

Literatur

  • 1 Levine J D, Gordon N C, Fields H L. The mechanism of placebo analgesia.  Lancet. 1978;  2 654-657
    PubMedGoogle Scholar
  • 2 Petrovic P, Kalso E, Petersson K M. et al . Placebo and opioid analgesia - imaging a shared neuronal network.  Science. 2002;  295 1737-1740
    CrossrefPubMedGoogle Scholar
  • 3 Benedetti F. Placebo and endogenous mechanisms of analgesia.  Handb Exp Pharmacol. 2007;  177 393-413
    PubMedGoogle Scholar
  • 4 Benedetti F, Mayberg H S, Wager T D. et al . Neurobiological mechanisms of the placebo effect.  J Neurosci. 2005;  25 10390-10402
    CrossrefPubMedGoogle Scholar
  • 5 Benedetti F, Rainero I, Pollo A. New insights into placebo analgesia.  Curr Opin Anaesthesiol. 2003;  16 515-519
    CrossrefPubMedGoogle Scholar
  • 6 Tfelt-Hansen P. Methodology of treatment trials for acute migraine attacks. In: Olesen J, Tfelt-Hansen P (eds) Headache Treatment: Trial Methodology and New Drugs. Philadelphia; Lippincott-Raven 1997: 111-117
    Google Scholar
  • 7 Tfelt-Hansen P, Henry P, Mulder L J. et al . The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine.  Lancet. 1995;  346 923-926
    CrossrefPubMedGoogle Scholar
  • 8 Henry P, Hiesseprovost O, Dillenschneider A. et al . Efficacy and tolerance of effervescent aspirin metoclopramide association in the treatment of migraine attack.  Presse Med. 1995;  24 254-258
    PubMedGoogle Scholar
  • 9 Diener H C. for the ASASUMAMIG Study Group . Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study.  Cephalalgia. 1999;  19 581-588
    CrossrefPubMedGoogle Scholar
  • 10 Bendtsen L, Mattsson P, Zwart J A. et al . Placebo response in clinical randomized trials of analgesics in migraine.  Cephalalgia. 2003;  23 487-490
    CrossrefPubMedGoogle Scholar
  • 11 Tfelt-Hansen P, Block G. et al, International Headache Society Clinical Trials Subcommitee . Guidelines for controlled trials of drugs in migraine: second edition.  Cephalalgia. 2000;  20 765-786
    CrossrefPubMedGoogle Scholar
  • 12 Ferrari M D, Roon K I, Lipton R B. et al . Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials.  Lancet. 2001;  358 1668-1675
    CrossrefPubMedGoogle Scholar
  • 13 Holroyd K A, Penzien D B, Cordingley G E. Propranolol in the management of recurrent migraine: a meta-analytic review.  Headache. 1991;  31 333-340
    CrossrefPubMedGoogle Scholar
  • 14 Mathew N T, Saper J R, Silberstein S D. et al . Migraine prophylaxis with divalproex.  Arch Neurol. 1995;  52 281-286
    PubMedGoogle Scholar
  • 15 Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study.  Cephalalgia. 1996;  16 257-263
    CrossrefPubMedGoogle Scholar
  • 16 Klapper J. on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group . Divalproex sodium in migraine prophylaxis: a dose-controlled study.  Cephalalgia. 1997;  17 103-108
    CrossrefPubMedGoogle Scholar
  • 17 Ven L LM van de, Franke C L, Koehler P J. et al . Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study.  Cephalalgia. 1997;  17 596-599
    CrossrefPubMedGoogle Scholar
  • 18 Diener H C, Foh M, Iaccarino C. et al . Cyclandelate in the prophylaxis of migraine: a randomised parallel, double-blind study in comparison with placebo and propranolol.  Cephalalgia. 1996;  16 441-447
    CrossrefPubMedGoogle Scholar
  • 19 Diener H C, Kronfeld K, Boewing G. et al . Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial.  Lancet Neurol. 2006;  5 310-316
    CrossrefPubMedGoogle Scholar
  • 20 Linde K, Streng A, Jurgens S. et al . Acupuncture for patients with migraine: a randomized controlled trial.  JAMA. 2005;  293 2118-2125
    CrossrefPubMedGoogle Scholar
  • 21 Craen A JM de, Tijssen J GP, Gans J de. et al . Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos.  J Neurol. 2000;  247 183-188
    PubMedGoogle Scholar
  • 22 Bausell R B, Lao L, Bergman S. et al . Is acupuncture analgesia an expectancy effect? Preliminary evidence based on participants' perceived assignments in two placebo-controlled trials.  Eval Health Prof. 2005;  28 9-26
    PubMedGoogle Scholar
  • 23 Geraud G, Olesen J, Pfaffenrath V. et al . Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.  Cephalalgia. 2000;  20 30-38
    CrossrefPubMedGoogle Scholar
  • 24 Diener H C, Tfelt-Hansen P, Dahlöf C. et al . Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control.  J Neurol. 2004;  251 943-950
    PubMedGoogle Scholar
  • 25 Brandes J, Saper J, Diamond M. et al . Topiramate for migraine prevention: a randomized controlled trial.  JAMA. 2004;  291 965-973
    CrossrefPubMedGoogle Scholar
  • 26 Bussone G, Diener H, Pfeil J. et al . Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials.  Int J Clin Pract. 2005;  59 961-968
    CrossrefPubMedGoogle Scholar
  • 27 Silberstein S D, Neto W, Schmitt J. et al . Topiramate in migraine prevention: results of a large controlled trial.  Arch Neurol. 2004;  61 490-495
    CrossrefPubMedGoogle Scholar
  • 28 Silberstein S D, Gobel H, Jensen R. et al . Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.  Cephalalgia. 2006;  26 790-800
    CrossrefPubMedGoogle Scholar
  • 29 Mathew N T, Frishberg B M, Gawel M. et al . Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.  Headache. 2005;  45 293-307
    CrossrefPubMedGoogle Scholar
  • 30 Diener H, Bussone G, Oene J Van. et al .Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 2007, in press
    Google Scholar
  • 31 Silvestrini M, Bartolini M, Coccia M. et al . Topiramate in the treatment of chronic migraine.  Cephalalgia. 2003;  23 820-824
    CrossrefPubMedGoogle Scholar
  • 32 Mathew N, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.  Headache. 2003;  43 962-974
    CrossrefPubMedGoogle Scholar
  • 33 Diener H. Eletriptan in migraine.  Exp Rev Neurotherapeutics. 2005;  5 43-54
    PubMedGoogle Scholar
  • 34 Goadsby P J, Lipton R B. Newer triptans: emphasis on rizatriptan.  Neurology. 2000;  55 S1-S2
    PubMedGoogle Scholar
  • 35 Diener H C. persönl. Mitteilung. 
    Google Scholar
  • 36 Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls.  Cephalalgia. 2005;  25 124-131
    CrossrefPubMedGoogle Scholar
  • 37 Lewis D, Ashwal S, Hershey A. et al . Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.  Neurology. 2004;  63 2215-2224
    CrossrefPubMedGoogle Scholar
  • 38 Visser W H, Winner P, Strohmaier K. et al . Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.  Headache. 2004;  44 891-899
    CrossrefPubMedGoogle Scholar
  • 39 Winner P, Lewis D, Visser H. et al . Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study.  Headache. 2002;  42 49-55
    CrossrefPubMedGoogle Scholar
  • 40 Geraud G, Lanteri-Minet M, Lucas C. et al . French guidelines for the diagnosis and management of migraine in adults and children.  Clin Ther. 2004;  26 1305-1318
    CrossrefPubMedGoogle Scholar
  • 41 Ahonen K, Hamalainen M L, Eerola M. et al . A randomized trial of rizatriptan in migraine attacks in children.  Neurology. 2006;  67 1135-1140
    CrossrefPubMedGoogle Scholar
  • 42 Lewis S W, Winner P, Wasiewski W. The placebo responder rate in children and adolescents.  Headache. 2005;  45 232-239
    CrossrefPubMedGoogle Scholar
  • 43 Ekbom K, Monstad I, Prusinski A. et al . Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study.  Acta Neurol Scand. 1993;  88 63-69
    PubMedGoogle Scholar
  • 44 Nilsson Rehmanl A IM, Laudon Meyer E L, Cordonnier C. et al . Placebo response in cluster headache trials: a review.  Cephalalgia. 2003;  23 504-510
    CrossrefPubMedGoogle Scholar
  • 45 Diener H, Matias-Guiu J, Hartung E. et al . Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily.  Cephalalgia. 2002;  22 209-221
    CrossrefPubMedGoogle Scholar
  • 46 Reuter U, Sanchez Del Rio M, Carpay J. et al . Placebo adverse events in headache trials: headache as an adverse event of placebo.  Cephalalgia. 2003;  23 496-503
    CrossrefPubMedGoogle Scholar
  • 47 Gauler T C, Weihrauch T R. Placebo. München, Wien, Baltimore; Urban & Schwarzenberg 1997
    Google Scholar
  • 48 Diener H C, Hartung E, Chrubasik J. et al . A comparative study of acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomised, controlled, double-blind, parallel group phase III study.  Cephalalgia. 2001;  21 140-144
    CrossrefPubMedGoogle Scholar

Prof. Dr. Hans-Christoph Diener, FAHA, FAAN

Direktor der Universitätsklinik für Neurologie, Universitätsklinikum Essen

Hufelandstraße 55

45147 Essen

Email: hans.diener@uni-duisburg-essen.de